Navigation Links
Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
Date:10/27/2008

SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc., (Nasdaq: NLTX), announced today that Peter Strumph, Chief Executive Officer, will present at the 7th Annual BIO Investor Forum on Thursday, October 30th, at 9:00 a.m. PT at The Palace Hotel in San Francisco.

Mr. Strumph will provide an overview of Nile and an update on its clinical development programs, including interim data from Nile's Phase 2a study for its lead compound, CD-NP, a novel chimeric peptide for the treatment of heart failure.

The presentation will be webcast live and can be accessed by visiting the Investor Relations section of Nile's website at http://www.nilethera.com. The webcast will be archived for 90 days.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical need. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure; 2NTX-99, a small molecule, pre-clinical, anti-atherothrombotic agent with nitric oxide donating properties; and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and unc
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nektar Therapeutics to Webcast R&D Day on November 12th
2. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
3. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
4. Leading Heart Specialist Joins Duska Therapeutics as Scientific Consultant
5. CV Therapeutics to Announce 2008 Third Quarter Financial Results on Thursday, November 6, 2008
6. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
7. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
8. Halozyme Therapeutics to Present at Upcoming Investor Conferences
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
10. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2008
11. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 HUYA Bioscience International (HUYA) today ... the Japan Society of HTLV-1, held this week at ... purpose of the Society is to promote research on ... of medical technology and research related to these fields ... "HUYA is proud to support this prestigious conference," ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Medicine, recently presented new data on the relationship of genetics and hypertension at ... Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts ...
(Date:8/26/2015)...  The Diabetes Research Institute (DRI), a Center ... School of Medicine, announced today that the first ... the first time a novel transplant technique for ... Phase I/II study builds upon decades of progress ... first step toward the development of the DRI ...
(Date:8/26/2015)... -- After litigating and negotiating patent infringement claims ... United States patent RE43,651 (the ,651 ... the United States without any admission or concession ... As a result of the parties, settlement, the US District ... dismissed the case without prejudice. Under the ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2
... TorreyPines Therapeutics, Inc. (Nasdaq: TPTX ) ... after consideration of potential strategic and financing alternatives, that ... and its stockholders to liquidate the Company,s assets and ... has unanimously approved a Plan of Liquidation and Dissolution ...
... David Nicholls and Martin Brand collaborate with Seahorse ... workshop and will share their years of experience ... Mass., May 29 Seahorse Bioscience, Inc., the ... based metabolic assays announced their first Cellular Bioenergetics ...
... Zeus Research & Development will be one of the ... invention of new devices in interventional gastroenterologyORANGEBURG, S.C., May ... and material science, announces it has been invited to ... 1, 2009. Zeus presenters Dr. Bruce Anneaux, Ph.D. and ...
Cached Biology Technology:TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 2TorreyPines Therapeutics Announces its Board of Directors' Approval of Plan of Liquidation and Dissolution 3New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 2New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the World's Leading Bioenergetics Researchers 3Zeus to Present at Digestive Disease Week in Chicago 2
(Date:8/11/2015)... -- Today, ZUK announced its Android smartphone Z1, featuring ... revenues in 2015 that relate to sales of FPC1155 for this ... 2,200 MSEK for 2015. Jörgen Lantto, CEO of FPC, ... smartphone manufacturer in China and we ... 155 for Z1 , ...
(Date:8/10/2015)... , August 10, 2015 The ... offers comprehensive analysis of the global border security ... generate revenues of $16.4bn in 2015. Now: Border ... is an example of the business critical issue you need ... read visiongain ,s objective analysis of how this will ...
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... within the immune system could help explain why younger people ... diagnosed with variant CJD are, on average, 28 years old ... as affected by the disease. Research at The Roslin ... within the immune system that attract corrupted proteins known ...
... Our brains, it turns out, are eco-friendly. A study published ... Venkatesh Murthy and Jakob Sorensen reveals that our brains have ... cells generate and propagate nerve impulses, or action potentials, by ... and out of the cells. Re-establishing the ion equilibrium after ...
... DIEGO, Oct. 13 CareFusion Corporation (NYSE: CFN ... announced the launch of the EnVe(TM) ventilator - a ... Weighing only 10 pounds, the EnVe ventilator is 70-80 ... the latest in portable and ventilation technology to help ...
Cached Biology News:Cell study explains why younger people more at risk of vCJD 2CareFusion Launches 10-Pound High-Performance Critical Care Ventilator in the U.S. 2CareFusion Launches 10-Pound High-Performance Critical Care Ventilator in the U.S. 3
Anti-human CD48/BLAST-1, clone MEM102, Monoclonal Antibody...
Raf-1 (C-12)-G...
... This DuoSet ELISA Development kit contains ... of sandwich ELISAs to measure natural and ... culture supernates and serum. Each kit contains ... fifteen 96-well plates, provided that the following ...
E1A (adenovirus early region 1)...
Biology Products: